{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:22:09Z","timestamp":1781590929909,"version":"3.54.5"},"reference-count":110,"publisher":"Bentham Science Publishers Ltd.","issue":"26","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2020,11,3]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>The article highlights an up-to-date progress in studies on structural and the remedial aspects\nof novel coronavirus 2019-nCoV, renamed as SARS-CoV-2, leading to the disease COVID-19, a pandemic.\nIn general, all CoVs including SARS-CoV-2 are spherical positive single-stranded RNA viruses\ncontaining spike (S) protein, envelope (E) protein, nucleocapsid (N) protein, and membrane (M) protein,\nwhere S protein has a Receptor-binding Domain (RBD) that mediates the binding to host cell receptor,\nAngiotensin Converting Enzyme 2 (ACE2). The article details the repurposing of some drugs to be tried\nfor COVID-19 and presents the status of vaccine development so far. Besides drugs and vaccines, the\nrole of Convalescent Plasma (CP) therapy to treat COVID-19 is also discussed.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026620666200922112300","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T07:23:52Z","timestamp":1600845832000},"page":"2362-2378","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2"],"prefix":"10.2174","volume":"20","author":[{"given":"Satya P.","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, Meerut-250005, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3390\/v2081803","volume":"2","author":"Woo P.C.","year":"2010","unstructured":"Woo P.C.; Huang Y.; Lau S.K.; Yuen K.Y.; Coronavirus genomics and bioinformatics analysis. Viruses 2010,2(8),1804-1820","journal-title":"Viruses"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1128\/JVI.06540-11","volume":"86","author":"Woo P.C.","year":"2012","unstructured":"Woo P.C.; Lau S.K.; Lam C.S.; Lau C.C.; Tsang A.K.; Lau J.H.; Bai R.; Teng J.L.; Tsang C.C.; Wang M.; Zheng B.J.; Chan K.H.; Yuen K.Y.; Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol 2012,86(7),3995-4008","journal-title":"J Virol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/pathogens9030186","volume":"9","author":"Ashour H.M.","year":"2020","unstructured":"Ashour H.M.; Elkhatib W.F.; Rahman M.M.; Elshabrawy H.A.; Elshabrawy H.A.; Insights into the recent 2019 novel coronavirus (SARS- CoV-2) in light of past human coronavirus outbreaks. Pathogens 2020,9(3),186","journal-title":"Pathogens"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa030747","volume":"348","author":"Drosten C.","year":"2003","unstructured":"Drosten C.; G\u00fcnther S.; Preiser W.; van der Werf S.; Brodt H.R.; Becker S.; Rabenau H.; Panning M.; Kolesnikova L.; Fouchier R.A.; Berger A.; Burgui\u00e8re A.M.; Cinatl J.; Eickmann M.; Escriou N.; Grywna K.; Kramme S.; Manuguerra J.C.; M\u00fcller S.; Rickerts V.; St\u00fcrmer M.; Vieth S.; Klenk H.D.; Osterhaus A.D.; Schmitz H.; Doerr H.W.; Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003,348(20),1967-1976","journal-title":"N Engl J Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","volume":"367","author":"Zaki A.M.","year":"2012","unstructured":"Zaki A.M.; van Boheemen S.; Bestebroer T.M.; Osterhaus A.D.; Fouchier R.A.; Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012,367(19),1814-1820","journal-title":"N Engl J Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"Zhu N.","year":"2020","unstructured":"Zhu N.; Zhang D.; Wang W.; Li X.; Yang B.; Song J.; Zhao X.; Huang B.; Shi W.; Lu R.; Niu P.; Zhan F.; Ma X.; Wang D.; Xu W.; Wu G.; Gao G.F.; Tan W.; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in china, 2019. N Engl J Med 2020,382(8),727-733","journal-title":"N Engl J Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1056\/NEJMc2001468","volume":"382","author":"Rothe C.","year":"2020","unstructured":"Rothe C.; Schunk M.; Sothmann P.; Bretzel G.; Froeschl G.; Wallrauch C.; Zimmer T.; Thiel V.; Janke C.; Guggemos W.; Seilmaier M.; Drosten C.; Vollmar P.; Zwirglmaier K.; Zange S.; W\u00f6lfel R.; Hoelscher M.; Transmission of 2019-nCoV infection from an asymptomatic contact in germany. N Engl J Med 2020,382(10),970-971","journal-title":"N Engl J Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"Lu R.","year":"2020","unstructured":"Lu R.; Zhao X.; Li J.; Niu P.; Yang B.; Wu H.; Wang W.; Song H.; Huang B.; Zhu N.; Bi Y.; Ma X.; Zhan F.; Wang L.; Hu T.; Zhou H.; Hu Z.; Zhou W.; Zhao L.; Chen J.; Meng Y.; Wang J.; Lin Y.; Yuan J.; Xie Z.; Ma J.; Liu W.J.; Wang D.; Xu W.; Holmes E.C.; Gao G.F.; Wu G.; Chen W.; Shi W.; Tan W.; Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020,395(10224),565-574","journal-title":"Lancet"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1073\/pnas.0805270106","volume":"106","author":"Barcena M.","year":"2009","unstructured":"Barcena M.; Oostergetel G.T.; Bartelink W.; Faas F.G.; Verkleij A.; Rottier P.J.; Koster A.J.; Bosch B.J.; Cryo-electron tomography of mouse hepatitis virus: Insights into the structure of the coronavirion. Proc Natl Acad Sci USA 2009,106(2),582-587","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"7918","DOI":"10.1128\/JVI.00645-06","volume":"80","author":"Neuman B.W.","year":"2006","unstructured":"Neuman B.W.; Adair B.D.; Yoshioka C.; Quispe J.D.; Orca G.; Kuhn P.; Milligan R.A.; Yeager M.; Buchmeier M.J.; Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy. J Virol 2006,80(16),7918-7928","journal-title":"J Virol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","volume":"1282","author":"Fehr A.R.","year":"2015","unstructured":"Fehr A.R.; Perlman S.; Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015,1282,1-23","journal-title":"Methods Mol Biol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3390\/v4061011","volume":"4","author":"Belouzard S.","year":"2012","unstructured":"Belouzard S.; Millet J.K.; Licitra B.N.; Whittaker G.R.; Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 2012,4(6),1011-1033","journal-title":"Viruses"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"7411","DOI":"10.1128\/JVI.00079-09","volume":"83","author":"Madu I.G.","year":"2009","unstructured":"Madu I.G.; Roth S.L.; Belouzard S.; Whittaker G.R.; Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide. J Virol 2009,83(15),7411-7421","journal-title":"J Virol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1016\/j.jmb.2017.10.017","volume":"429","author":"Lai A.L.","year":"2017","unstructured":"Lai A.L.; Millet J.K.; Daniel S.; Freed J.H.; Whittaker G.R.; The SARS-CoV fusion peptide forms an extended bipartite fusion platform that perturbs membrane order in a calcium-dependent manner. J Mol Biol 2017,429(24),3875-3892","journal-title":"J Mol Biol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12985-019-1182-0","volume":"16","author":"Schoeman D.","year":"2019","unstructured":"Schoeman D.; Fielding B.C.; Coronavirus envelope protein: current knowledge. Virol J 2019,16(1),69","journal-title":"Virol J"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11373-005-9035-9","volume":"13","author":"Chang C.K.","year":"2006","unstructured":"Chang C.K.; Sue S.C.; Yu T.H.; Hsieh C.M.; Tsai C.K.; Chiang Y.C.; Lee S.J.; Hsiao H.H.; Wu W.J.; Chang W.L.; Lin C.H.; Huang T.H.; Modular organization of SARS coronavirus nucleocapsid protein. J Biomed Sci 2006,13(1),59-72","journal-title":"J Biomed Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"7221","DOI":"10.1128\/JVI.00440-09","volume":"83","author":"Hurst K.R.","year":"2009","unstructured":"Hurst K.R.; Koetzner C.A.; Masters P.S.; Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein. J Virol 2009,83(14),7221-7234","journal-title":"J Virol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"11318","DOI":"10.1128\/JVI.01052-08","volume":"82","author":"Siu Y.L.","year":"2008","unstructured":"Siu Y.L.; Teoh K.T.; Lo J.; Chan C.M.; Kien F.; Escriou N.; Tsao S.W.; Nicholls J.M.; Altmeyer R.; Peiris J.S.; Bruzzone R.; Nal B.; The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J Virol 2008,82(22),11318-11330","journal-title":"J Virol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2217\/fvl-2018-0144","volume":"14","author":"J. Alsaadi E.A.","year":"2019","unstructured":"J. Alsaadi E.A.; Jones I.M.; Membrane binding proteins of coronaviruses. Future Virol 2019,14(4),275-286","journal-title":"Future Virol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1126\/science.1118391","volume":"310","author":"Li W.","year":"2005","unstructured":"Li W.; Shi Z.; Yu M.; Ren W.; Smith C.; Epstein J.H.; Wang H.; Crameri G.; Hu Z.; Zhang H.; Zhang J.; McEachern J.; Field H.; Daszak P.; Eaton B.T.; Zhang S.; Wang L.F.; Bats are natural reservoirs of SARS-like coronaviruses. Science 2005,310(5748),676-679","journal-title":"Science"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"14040","DOI":"10.1073\/pnas.0506735102","volume":"102","author":"Lau S.K.","year":"2005","unstructured":"Lau S.K.; Woo P.C.; Li K.S.; Huang Y.; Tsoi H.W.; Wong B.H.; Wong S.S.; Leung S.Y.; Chan K.H.; Yuen K.Y.; Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 2005,102(39),14040-14045","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"6134","DOI":"10.1128\/JVI.78.12.6134-6142.2004","volume":"78","author":"Hofmann H.","year":"2004","unstructured":"Hofmann H.; Hattermann K.; Marzi A.; Gramberg T.; Geier M.; Krumbiegel M.; Kuate S.; Uberla K.; Niedrig M.; P\u00f6hlmann S.; S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol 2004,78(12),6134-6142","journal-title":"J Virol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"Li W.","year":"2003","unstructured":"Li W.; Moore M.J.; Vasilieva N.; Sui J.; Wong S.K.; Berne M.A.; Somasundaran M.; Sullivan J.L.; Luzuriaga K.; Greenough T.C.; Choe H.; Farzan M.; Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003,426(6965),450-454","journal-title":"Nature"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/sj.emboj.7600640","volume":"24","author":"Li W.","year":"2005","unstructured":"Li W.; Zhang C.; Sui J.; Kuhn J.H.; Moore M.J.; Luo S.; Wong S.K.; Huang I.C.; Xu K.; Vasilieva N.; Murakami A.; He Y.; Marasco W.A.; Guan Y.; Choe H.; Farzan M.; Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 2005,24(8),1634-1643","journal-title":"EMBO J"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"Wrapp D.","year":"2020","unstructured":"Wrapp D.; Wang N.; Corbett K.S.; Goldsmith J.A.; Hsieh C.L.; Abiona O.; Graham B.S.; McLellan J.S.; Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020,367(6483),1260-1263","journal-title":"Science"},{"key":"ref=26","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104742","volume":"176","author":"Coutard B.","year":"2020","unstructured":"Coutard B.; Valle C.; de Lamballerie X.; Canard B.; Seidah N.G.; Decroly E.; The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res 2020,176","journal-title":"Antiviral Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1128\/JVI.02615-14","volume":"89","author":"Li F.","year":"2015","unstructured":"Li F.; Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J Virol 2015,89(4),1954-1964","journal-title":"J Virol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"6984","DOI":"10.1128\/JVI.00442-08","volume":"82","author":"Li F.","year":"2008","unstructured":"Li F.; Structural analysis of major species barriers between humans and palm civets for severe acute respiratory syndrome coronavirus infections. J Virol 2008,82(14),6984-6991","journal-title":"J Virol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1126\/science.1116480","volume":"309","author":"Li F.","year":"2005","unstructured":"Li F.; Li W.; Farzan M.; Harrison S.C.; Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005,309(5742),1864-1868","journal-title":"Science"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"8904","DOI":"10.1074\/jbc.M111.325803","volume":"287","author":"Wu K.","year":"2012","unstructured":"Wu K.; Peng G.; Wilken M.; Geraghty R.J.; Li F.; Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus. J Biol Chem 2012,287(12),8904-8911","journal-title":"J Biol Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JVI.00127-20","volume":"94","author":"Wan Y.","year":"2020","unstructured":"Wan Y.; Shang J.; Graham R.; Baric R.S.; Li F.; Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020,94(7),1-9","journal-title":"J Virol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"Walls A.C.","year":"2020","unstructured":"Walls A.C.; Park Y-J.; Tortorici M.A.; Wall A.; McGuire A.T.; Veesler D.; Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020,181(2),281-292.e6","journal-title":"Cell"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1099\/0022-1317-81-4-853","volume":"81","author":"Ziebuhr J.","year":"2000","unstructured":"Ziebuhr J.; Snijder E.J.; Gorbalenya A.E.; Virus-encoded proteinases and proteolytic processing in the Nidovirales. J Gen Virol 2000,81(Pt 4),853-879","journal-title":"J Gen Virol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"7117","DOI":"10.1093\/nar\/gkg916","volume":"31","author":"Xu X.","year":"2003","unstructured":"Xu X.; Liu Y.; Weiss S.; Arnold E.; Sarafianos S.G.; Ding J.; Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Res 2003,31(24),7117-7130","journal-title":"Nucleic Acids Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","volume":"3","author":"Li F.","year":"2016","unstructured":"Li F.; Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 2016,3(1),237-261","journal-title":"Annu Rev Virol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"8801","DOI":"10.1128\/JVI.77.16.8801-8811.2003","volume":"77","author":"Bosch B.J.","year":"2003","unstructured":"Bosch B.J.; van der Zee R.; de Haan C.A.; Rottier P.J.; The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 2003,77(16),8801-8811","journal-title":"J Virol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"11157","DOI":"10.1073\/pnas.1708727114","volume":"114","author":"Walls A.C.","year":"2017","unstructured":"Walls A.C.; Tortorici M.A.; Snijder J.; Xiong X.; Bosch B.J.; Rey F.A.; Veesler D.; Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proc Natl Acad Sci USA 2017,114(42),11157-11162","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/cr.2016.152","volume":"27","author":"Gui M.","year":"2017","unstructured":"Gui M.; Song W.; Zhou H.; Xu J.; Chen S.; Xiang Y.; Wang X.; Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res 2017,27(1),119-129","journal-title":"Cell Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","volume":"114","author":"Pallesen J.","year":"2017","unstructured":"Pallesen J.; Wang N.; Corbett K.S.; Wrapp D.; Kirchdoerfer R.N.; Turner H.L.; Cottrell C.A.; Becker M.M.; Wang L.; Shi W.; Kong W.P.; Andres E.L.; Kettenbach A.N.; Denison M.R.; Chappell J.D.; Graham B.S.; Ward A.B.; McLellan J.S.; Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci USA 2017,114(35),E7348-E7357","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.cell.2018.12.028","volume":"176","author":"Walls A.C.","year":"2019","unstructured":"Walls A.C.; Xiong X.; Park Y-J.; Tortorici M.A.; Snijder J.; Quispe J.; Cameroni E.; Gopal R.; Dai M.; Lanzavecchia A.; Zambon M.; Rey F.A.; Corti D.; Veesler D.; Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. Cell 2019,176(5),1026-1039","journal-title":"Cell"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"15092","DOI":"10.1038\/ncomms15092","volume":"8","author":"Yuan Y.","year":"2017","unstructured":"Yuan Y.; Cao D.; Zhang Y.; Ma J.; Qi J.; Wang Q.; Lu G.; Wu Y.; Yan J.; Shi Y.; Zhang X.; Gao G.F.; Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat Commun 2017,8,15092","journal-title":"Nat Commun"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"Yan R.","year":"2020","unstructured":"Yan R.; Zhang Y.; Li Y.; Xia L.; Guo Y.; Zhou Q.; Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020,367(6485),1444-1448","journal-title":"Science"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","volume":"87","author":"Donoghue M.","year":"2000","unstructured":"Donoghue M.; Hsieh F.; Baronas E.; Godbout K.; Gosselin M.; Stagliano N.; Donovan M.; Woolf B.; Robison K.; Jeyaseelan R.; Breitbart R.E.; Acton S.; A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000,87(5),E1-E9","journal-title":"Circ Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"17132","DOI":"10.1074\/jbc.M006723200","volume":"276","author":"Zhang H.","year":"2001","unstructured":"Zhang H.; Wada J.; Hida K.; Tsuchiyama Y.; Hiragushi K.; Shikata K.; Wang H.; Lin S.; Kanwar Y.S.; Makino H.; Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. J Biol Chem 2001,276(20),17132-17139","journal-title":"J Biol Chem"},{"key":"ref=45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007236","volume":"14","author":"Song W.","year":"2018","unstructured":"Song W.; Gui M.; Wang X.; Xiang Y.; Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog 2018,14(8)","journal-title":"PLoS Pathog"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1021\/acs.jproteome.0c00129","volume":"19","author":"Zhang C.","year":"2020","unstructured":"Zhang C.; Zheng W.; Huang X.; Bell E.W.; Zhou X.; Zhang Y.; Protein structure and sequence reanalysis of 2019-nCoV genome refutes snakes as its intermediate host and the unique similarity between its spike protein insertions and HIV-1. J Proteome Res 2020,19(4),1351-1360","journal-title":"J Proteome Res"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","volume":"117","author":"Shang J.","year":"2020","unstructured":"Shang J.; Wan Y.; Luo C.; Ye G.; Geng O.; Auerbach A.; Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci USA 2020,117(21),11727-11734","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"Hoffmann M.","year":"2020","unstructured":"Hoffmann M.; Kleine-Weber H.; Schroeder S.; Kr\u00fcger N.; Herrler T.; Erichsen S.; Schiergens T.S.; Herrler G.; Wu N.H.; Nitsche A.; M\u00fcller M.A.; Drosten C.; P\u00f6hlmann S.; SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020,181(2),271-280.e8","journal-title":"Cell"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","volume":"11","author":"Ou X.","year":"2020","unstructured":"Ou X.; Liu Y.; Lei X.; Li P.; Mi D.; Ren L.; Guo L.; Guo R.; Chen T.; Hu J.; Xiang Z.; Mu Z.; Chen X.; Chen J.; Hu K.; Jin Q.; Wang J.; Qian Z.; Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 2020,11(1),1620","journal-title":"Nat Commun"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrmicro2090","volume":"7","author":"Du L.","year":"2009","unstructured":"Du L.; He Y.; Zhou Y.; Liu S.; Zheng B.J.; Jiang S.; The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol 2009,7(3),226-236","journal-title":"Nat Rev Microbiol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"13473","DOI":"10.1038\/ncomms13473","volume":"7","author":"Du L.","year":"2016","unstructured":"Du L.; Tai W.; Yang Y.; Zhao G.; Zhu Q.; Sun S.; Liu C.; Tao X.; Tseng C.K.; Perlman S.; Jiang S.; Zhou Y.; Li F.; Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat Commun 2016,7,13473","journal-title":"Nat Commun"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"Shang J.","year":"2020","unstructured":"Shang J.; Ye G.; Shi K.; Wan Y.; Luo C.; Aihara H.; Geng Q.; Auerbach A.; Li F.; Structural basis of receptor recognition by SARS-CoV-2. Nature 2020,581(7807),221-224","journal-title":"Nature"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.3390\/molecules25102271","volume":"25","author":"Rahman N.","year":"2020","unstructured":"Rahman N.; Basharat Z.; Yousuf M.; Castaldo G.; Rastrelli L.; Khan H.; Virtual screening of natural products against type II transmembrane serine protease (TMPRSS2), the priming agent of coronavirus 2 (SARS-CoV-2). Molecules 2020,25(10),2271","journal-title":"Molecules"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"e01815","DOI":"10.1128\/JVI.01815-18","volume":"93","author":"Iwata-Yoshikawa N.","year":"2019","unstructured":"Iwata-Yoshikawa N.; Okamura T.; Shimizu Y.; Hasegawa H.; Takeda M.; Nagata N.; TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J Virol 2019,93(6),e01815-e01818","journal-title":"J Virol"},{"key":"ref=55","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2020.104272","volume":"81","author":"Fahmi M.","year":"2020","unstructured":"Fahmi M.; Kubota Y.; Ito M.; Nonstructural proteins NS7b and NS8 are likely to be phylogenetically associated with evolution of 2019-nCoV. Infect Genet Evol 2020,81","journal-title":"Infect Genet Evol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.virusres.2016.04.001","volume":"220","author":"van der Hoeven B.","year":"2016","unstructured":"van der Hoeven B.; Oudshoorn D.; Koster A.J.; Snijder E.J.; Kikkert M.; B\u00e1rcena M.; Biogenesis and architecture of arterivirus replication organelles. Virus Res 2016,220,70-90","journal-title":"Virus Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"e01658","DOI":"10.1128\/mBio.01658-17","volume":"8","author":"Oudshoorn D.","year":"2017","unstructured":"Oudshoorn D.; Rijs K.; Limpens R.W.A.L.; Groen K.; Koster A.J.; Snijder E.J.; Kikkert M.; B\u00e1rcena M.; Expression and cleavage of middle east respiratory syndrome coronavirus nsp3-4 polyprotein induce the formation of double-membrane vesicles that mimic those associated with coronaviral RNA replication. MBio 2017,8(6),e01658-e17","journal-title":"MBio"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","volume":"295","author":"Gordon C.J.","year":"2020","unstructured":"Gordon C.J.; Tchesnokov E.P.; Woolner E.; Perry J.K.; Feng J.Y.; Porter D.P.; Gotte M.; Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 2020,295(15),4773-4779","journal-title":"J Biol Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"Wang M.","year":"2020","unstructured":"Wang M.; Cao R.; Zhang L.; Yang X.; Liu J.; Xu M.; Shi Z.; Hu Z.; Zhong W.; Xiao G.; Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020,30(3),269-271","journal-title":"Cell Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","volume":"295","author":"Gordon C.J.","year":"2020","unstructured":"Gordon C.J.; Tchesnokov E.P.; Feng J.Y.; Porter D.P.; G\u00f6tte M.; The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 2020,295(15),4773-4779","journal-title":"J Biol Chem"},{"key":"ref=61","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3653","volume":"9","author":"Sheahan T.P.","year":"2017","unstructured":"Sheahan T.P.; Sims A.C.; Graham R.L.; Menachery V.D.; Gralinski L.E.; Case J.B.; Leist S.R.; Pyrc K.; Feng J.Y.; Trantcheva I.; Bannister R.; Park Y.; Babusis D.; Clarke M.O.; Mackman R.L.; Spahn J.E.; Palmiotti C.A.; Siegel D.; Ray A.S.; Cihlar T.; Jordan R.; Denison M.R.; Baric R.S.; Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017,9(396)","journal-title":"Sci Transl Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","volume":"11","author":"Sheahan T.P.","year":"2020","unstructured":"Sheahan T.P.; Sims A.C.; Leist S.R.; Sch\u00e4fer A.; Won J.; Brown A.J.; Montgomery S.A.; Hogg A.; Babusis D.; Clarke M.O.; Spahn J.E.; Bauer L.; Sellers S.; Porter D.; Feng J.Y.; Cihlar T.; Jordan R.; Denison M.R.; Baric R.S.; Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020,11(1),222","journal-title":"Nat Commun"},{"key":"ref=63","year":"2020","unstructured":"ClinicalTrials.gov. Adaptive COVID-19 Treatment Trial (ACTT),2020"},{"key":"ref=64","year":"2020","unstructured":"Gilead.Gilead announces results from phase 3 trial of investigational\nantiviral remdesivir in patients with severe COVID-19.  Gilead\nSciences Available from: 2020","journal-title":"Gilead\nSciences"},{"key":"ref=65","year":"2020","unstructured":"FDA. Letter of Authorization, EUA for Veklury (remdesivir).2020"},{"key":"ref=66","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1767691","author":"Hendaus M.A.","year":"2020","unstructured":"Hendaus M.A.; Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary. J Biomol Struct Dyn (in press)2020","journal-title":"J Biomol Struct Dyn"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1767210","author":"Babadaei M.M.N.","year":"2020","unstructured":"Babadaei M.M.N.; Hasan A.; Vahdani Y.; Bloukh S.H.; Sharifi M.; Kachooei E.; Haghighat S.; Falahati M.; Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase. J Biomol Struct Dyn (online ahead of print)2020,1-9","journal-title":"J Biomol Struct Dyn"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","volume":"6","author":"Xu J.","year":"2020","unstructured":"Xu J.; Shi P-Y.; Li H.; Zhou J.; Broad spectrum antiviral agent niclosamide and its therapeutic potential. ACS Infect Dis 2020,6(5),909-915","journal-title":"ACS Infect Dis"},{"key":"ref=69","author":"Mehra M.R.","year":"2020","unstructured":"Mehra M.R.; Desai S.S.; Ruschitzka F.; Patel A.N.; Hydroxychloroquine or chloroquine with or without amacrolide for treatment of COVID-19: a multinational registry analysis. The Lancet (In Press)2020","journal-title":"The Lancet"},{"key":"ref=70","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104787","volume":"178","author":"Caly L.","year":"2020","unstructured":"Caly L.; Druce J.D.; Catton M.G.; Jans D.A.; Wagstaff K.M.; The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020,178","journal-title":"Antiviral Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1208\/s12248-007-9000-9","volume":"10","author":"Gonz\u00e1lez Canga A.","year":"2008","unstructured":"Gonz\u00e1lez Canga A.; Sahag\u00fan Prieto A.M.; Diez Li\u00e9bana M.J.; Fern\u00e1ndez Mart\u00ednez N.; Sierra Vega M.; Garc\u00eda Vieitez J.J.; The pharmacokinetics and interactions of ivermectin in humans--a mini-review. AAPS J 2008,10(1),42-46","journal-title":"AAPS J"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12941-020-00368-w","volume":"19","author":"Sharun K.","year":"2020","unstructured":"Sharun K.; Dhama K.; Patel S.K.; Pathak M.; Tiwari R.; Singh B.R.; Sah R.; Bonilla-Aldana D.K.; Rodriguez-Morales A.J.; Leblebicioglu H.; Ivermectin, a new candidate therapeutic against SARS-CoV-2\/COVID-19. Ann Clin Microbiol Antimicrob 2020,19(1),23","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref=73","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1889","author":"Schmith V.D.","year":"2020","unstructured":"Schmith V.D.; Zhou J.; Lohmer L.R.L.; The approved dose of\nivermectin alone is not the ideal dose for the treatment of COVID-\n19.  Clin Pharmacol Therap (online ahead of print)2020","journal-title":"Clin Pharmacol Therap"},{"key":"ref=74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.017","volume":"82","author":"Patr\u00ec A.","year":"2020","unstructured":"Patr\u00ec A.; Fabbrocini G.; Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment? J Am Acad Dermatol 2020,82(6)","journal-title":"J Am Acad Dermatol"},{"key":"ref=75","author":"Mori M.","year":"2020","unstructured":"Mori M.; Capasso C.; Carta F.; William a Donald W. A.; Supuran C. T.; A deadly spillover: SARS-CoV-2 outbreak.  Expert Opin\nTherap Pat (online ahead of print)2020","journal-title":"Expert Opin\nTherap Pat"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/jmv.25729","volume":"92","author":"Yao T-T.","year":"2020","unstructured":"Yao T-T.; Qian J-D.; Zhu W-Y.; Wang Y.; Wang G.Q.; A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol 2020,92(6),556-563","journal-title":"J Med Virol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.antiviral.2017.12.015","volume":"150","author":"Lin M.H.","year":"2018","unstructured":"Lin M.H.; Moses D.C.; Hsieh C.H.; Cheng S.C.; Chen Y.H.; Sun C.Y.; Chou C.Y.; Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antiviral Res 2018,150,155-163","journal-title":"Antiviral Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","volume":"19","author":"Li G.","year":"2020","unstructured":"Li G.; De Clercq E.; Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020,19(3),149-150","journal-title":"Nat Rev Drug Discov"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","volume":"6","author":"Liu C.","year":"2020","unstructured":"Liu C.; Zhou Q.; Li Y.; Garner L.V.; Watkins S.P.; Carter L.J.; Smoot J.; Gregg A.C.; Daniels A.D.; Jervey S.; Albaiu D.; Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 2020,6(3),315-331","journal-title":"ACS Cent Sci"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1126\/science.abb4489","volume":"368","author":"Dai W.","year":"2020","unstructured":"Dai W.; Zhang B.; Jiang X-M.; Su H.; Li J.; Zhao Y.; Xie X.; Jin Z.; Peng J.; Liu F.; Li C.; Li Y.; Bai F.; Wang H.; Cheng X.; Cen X.; Hu S.; Yang X.; Wang J.; Liu X.; Xiao G.; Jiang H.; Rao Z.; Zhang L.K.; Xu Y.; Yang H.; Liu H.; Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 2020,368(6497),1331-1335","journal-title":"Science"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"Zhang L.","year":"2020","unstructured":"Zhang L.; Lin D.; Sun X.; Curth U.; Drosten C.; Sauerhering L.; Becker S.; Rox K.; Hilgenfeld R.; Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science 2020,368(6489),409-412","journal-title":"Science"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"8312","DOI":"10.1021\/acsomega.0c00772","volume":"5","author":"Phuong B.T.","year":"2020","unstructured":"Phuong B.T.; My T.T.A.; Hai N.T.T.; Investigation into SARS-CoV-2 resistance of compounds in garlic essential oil. ACS Omega 2020,5(14),8312-8320","journal-title":"ACS Omega"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","volume":"6","author":"Liu J.","year":"2020","unstructured":"Liu J.; Cao R.; Xu M.; Wang X.; Zhang H.; Hu H.; Li Y.; Hu Z.; Zhong W.; Wang M.; Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020,6,16","journal-title":"Cell Discov"},{"key":"ref=84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105923","volume":"55","author":"Colson P.","year":"2020","unstructured":"Colson P.; Rolain J.M.; Raoult D.; Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents 2020,55(3)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223- y","volume":"582","author":"Jin Z.","year":"2019","unstructured":"Jin Z.; Du X.; Xu Y.; Deng Y.; Liu M.; Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature 2019,582,289-293","journal-title":"Nature"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"7058","DOI":"10.1021\/acs.jpclett.0c02278","volume":"11","author":"Batra R.","year":"2020","unstructured":"Batra R.; Chan H.; Kamath G.; Ramprasad R.; Cherukara M.J.; Sankaranarayanan S.K.R.S.; Screening of therapeutic agents for COVID-19 using machine learning and ensemble docking studies. J Phys Chem Lett 2020,11(17),7058-7065","journal-title":"J Phys Chem Lett"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","volume":"19","author":"Thanh Le T.","year":"2020","unstructured":"Thanh Le T.; Andreadakis Z.; Kumar A.; G\u00f3mez Rom\u00e1n R.; Tollefsen S.; Saville M.; Mayhew S.; The COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020,19(5),305-306","journal-title":"Nat Rev Drug Discov"},{"key":"ref=88","author":"Peel M.","year":"2020","unstructured":"Peel M.; Cost of vaccinating billions against COVID-19 put at more\nthan $20Bn. Available from: 2020"},{"key":"ref=89","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.19.955484doi","author":"Fast E.","year":"2020.","unstructured":"Fast E.; Altman R.B.; Chen B.; Potential T-cell and B-cell epitopes of 2019-nCoV. bioRxiv (in press)2020.","journal-title":"bioRxiv"},{"key":"ref=90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002829","volume":"8","author":"Kringelum J.V.","year":"2012","unstructured":"Kringelum J.V.; Lundegaard C.; Lund O.; Nielsen M.; Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLOS Comput Biol 2012,8(12)","journal-title":"PLOS Comput Biol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","volume":"9","author":"Tian X.","year":"2020","unstructured":"Tian X.; Li C.; Huang A.; Xia S.; Lu S.; Shi Z.; Lu L.; Jiang S.; Yang Z.; Wu Y.; Ying T.; Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 2020,9(1),382-385","journal-title":"Emerg Microbes Infect"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/rmv.405","volume":"13","author":"Takada A.","year":"2003","unstructured":"Takada A.; Kawaoka Y.; Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 2003,13(6),387-398","journal-title":"Rev Med Virol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.vaccine.2006.08.011","volume":"25","author":"Kam Y.W.","year":"2007","unstructured":"Kam Y.W.; Kien F.; Roberts A.; Cheung Y.C.; Lamirande E.W.; Vogel L.; Chu S.L.; Tse J.; Guarner J.; Zaki S.R.; Subbarao K.; Peiris M.; Nal B.; Altmeyer R.; Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine 2007,25(4),729-740","journal-title":"Vaccine"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.micinf.2020.02.006","volume":"22","author":"Tetro J.A.","year":"2020","unstructured":"Tetro J.A.; Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect 2020,22(2),72-73","journal-title":"Microbes Infect"},{"key":"ref=95","author":"Lv N.","year":"2020.","unstructured":"Lv N.; Wu N.C.; Tsang O.T.Y.; Yuan M.; Perera R.A.P.M.; Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. bioRxiv (in press)2020.","journal-title":"bioRxiv"},{"key":"ref=96","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2020.20249","volume":"150","author":"Negro F.","year":"2020","unstructured":"Negro F.; Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis? Swiss Med Wkly 2020,150","journal-title":"Swiss Med Wkly"},{"key":"ref=97","volume":"2020","author":"Darrell R.","year":"2020","unstructured":"Darrell R.; Malone R.W.; Medical countermeasures analysis of 2019-nCoV and vaccine risks for antibody-dependent enhancement (ADE). Preprints 2020,2020","journal-title":"Preprints"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"Duan K.","year":"2020","unstructured":"Duan K.; Liu B.; Li C.; Zhang H.; Yu T.; Qu J.; Zhou M.; Chen L.; Meng S.; Hu Y.; Peng C.; Yuan M.; Huang J.; Wang Z.; Yu J.; Gao X.; Wang D.; Yu X.; Li L.; Zhang J.; Wu X.; Li B.; Xu Y.; Chen W.; Peng Y.; Hu Y.; Lin L.; Liu X.; Huang S.; Zhou Z.; Zhang L.; Wang Y.; Zhang Z.; Deng K.; Xia Z.; Gong Q.; Zhang W.; Zheng X.; Liu Y.; Yang H.; Zhou D.; Yu D.; Hou J.; Shi Z.; Chen S.; Chen Z.; Zhang X.; Yang X.; Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020,117(17),9490-9496","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1021\/acscentsci.0c00644","volume":"6","author":"Ariel H.","year":"2020","unstructured":"Ariel H.; Thames, Kristy L. Wolniak, Samuel I. Stupp, and Michael C. Jewett. Principles Learned from the international race to develop a safe and effective COVID-19 vaccine. ACS Cent Sci 2020,6(8),1341-1347","journal-title":"ACS Cent Sci"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1101\/2020.03.30.20047365","volume":"20","author":"Wu F.","year":"2020","unstructured":"Wu F.; Wang A.; Liu M.; Wang Q.; Chen J.; Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. Lancet Infect Dis 2020,20,352","journal-title":"Lancet Infect Dis"},{"key":"ref=101","author":"Zost S.J.","year":"2020","unstructured":"Zost S.J.; Gilchuk P.; Chen R.E.; Case J.B.; Reidy J.X.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Bioarxiv (in press)2020","journal-title":"Bioarxiv"},{"key":"ref=102","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc7520","author":"Rogers T.F.","year":"2020","unstructured":"Rogers T.F.; Zhao F.; Huang D.; Beutler N.; Burns A.; He W.T.; Limbo O.; Smith C.; Song G.; Woehl J.; Yang L.; Abbott R.K.; Callaghan S.; Garcia E.; Hurtado J.; Parren M.; Peng L.; Ricketts J.; Ricciardi M.J.; Rawlings S.A.; Smith D.M.; Nemazee D.; Teijaro J.R.; Voss J.E.; Andrabi R.; Briney B.; Landais E.; Sok D.; Jardine J.G.; Burton D.R.; Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv 2020","journal-title":"bioRxiv"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"Robbiani D.F.","year":"2020","unstructured":"Robbiani D.F.; Gaebler C.; Muecksch F.; Lorenzi J.C.C.; Wang Z.; Cho A.; Agudelo M.; Barnes C.O.; Gazumyan A.; Finkin S.; H\u00e4ggl\u00f6f T.; Oliveira T.Y.; Viant C.; Hurley A.; Hoffmann H.H.; Millard K.G.; Kost R.G.; Cipolla M.; Gordon K.; Bianchini F.; Chen S.T.; Ramos V.; Patel R.; Dizon J.; Shimeliovich I.; Mendoza P.; Hartweger H.; Nogueira L.; Pack M.; Horowitz J.; Schmidt F.; Weisblum Y.; Michailidis E.; Ashbrook A.W.; Waltari E.; Pak J.E.; Huey-Tubman K.E.; Koranda N.; Hoffman P.R.; West A.P.; Rice C.M.; Hatziioannou T.; Bjorkman P.J.; Bieniasz P.D.; Caskey M.; Nussenzweig M.C.; Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020,584(7821),437-442","journal-title":"Nature"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","volume":"24","author":"Cheng Y.","year":"2005","unstructured":"Cheng Y.; Wong R.; Soo Y.O.Y.; Wong W.S.; Lee C.K.; Ng M.H.; Chan P.; Wong K.C.; Leung C.B.; Cheng G.; Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005,24(1),44-46","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMc070359","volume":"357","author":"Zhou B.","year":"2007","unstructured":"Zhou B.; Zhong N.; Guan Y.; Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007,357(14),1450-1451","journal-title":"N Engl J Med"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/cid\/ciq106","volume":"52","author":"Hung I.F.","year":"2011","unstructured":"Hung I.F.; To K.K.W.; Lee C-K.; Lee K.L.; Chan K.; Yan W.W.; Liu R.; Watt C.L.; Chan W.M.; Lai K.Y.; Koo C.K.; Buckley T.; Chow F.L.; Wong K.K.; Chan H.S.; Ching C.K.; Tang B.S.; Lau C.C.; Li I.W.; Liu S.H.; Chan K.H.; Lin C.K.; Yuen K.Y.; Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011,52(4),447-456","journal-title":"Clin Infect Dis"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3851\/IMP3243","volume":"23","author":"Ko J-H.","year":"2018","unstructured":"Ko J-H.; Seok H.; Cho S.Y.; Ha Y.E.; Baek J.Y.; Kim S.H.; Kim Y.J.; Park J.K.; Chung C.R.; Kang E.S.; Cho D.; M\u00fcller M.A.; Drosten C.; Kang C.I.; Chung D.R.; Song J.H.; Peck K.R.; Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther (Lond) 2018,23(7),617-622","journal-title":"Antivir Ther (Lond)"},{"key":"ref=108","author":"Van Beusekom M.","year":"2020","unstructured":"Van Beusekom M.; Autopsies of COVID-19 patients reveal clotting concerns. Available from: 2020"},{"key":"ref=109","author":"Gates B.","year":"2020","unstructured":"Gates B.; The first modern pandemic. The scientific advances we\nneed to stop COVID-19. Available from: 2020"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.2147\/DDDT.S271754","volume":"14","author":"Liu G.","year":"2020","unstructured":"Liu G.; Hong T.; Yang J.; A single large dose of vitamin D could be used as a means of coronavirus disease 2019 prevention and treatment. Drug Des Devel Ther 2020,14,3429-3434","journal-title":"Drug Des Devel Ther"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/186172","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/186172\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/186172","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T12:20:03Z","timestamp":1619180403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/186172\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":110,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2020,11,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026620666200922112300","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}